Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGT9486+Sunitinib vs. Sunitinib in Gastrointestinal Stromal Tumors
NCT05208047Phase 3Recruiting
- Sponsor
- Cogent Biosciences
- Start
- Apr 2022
- Primary completion
- Sep 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 22
01
Overview
A Phase 3 trial of bezuclastinib in gastrointestinal stromal tumor (GIST), sponsored by Cogent Biosciences. Started Apr 2022; status: recruiting.
02
Drugs
bezuclastinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT05208047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05208047.